Social Psychiatry and Psychiatric Epidemiology

, Volume 40, Issue 9, pp 707–717 | Cite as

The European Schizophrenia Cohort

A naturalistic prognostic and economic study
  • Paul E. Bebbington
  • Matthias Angermeyer
  • Jean-Michel Azorin
  • Traolach Brugha
  • Reinhold Kilian
  • Sonia Johnson
  • Mondher Toumi
  • Åsa Kornfeld
  • EuroSC Research Group
Original Investigation

Abstract

Background

Schizophrenia has a variety of clinical profiles, disabilities and outcomes requiring responsive management and the devotion of considerable resources. The primary objective of the European Schizophrenia Cohort (EuroSC) is to relate the types of treatment and methods of care to clinical outcome. Secondary objectives include the assessment of treatment needs in relation to outcome, the calculation of resource consumption associated with different methods of care, and the identification of prognostic factors.

Method

EuroSC is a naturalistic follow-up of a cohort of people aged 18 to 64 years, suffering from schizophrenia and in contact with secondary psychiatric services. The study was done in nine European centres, in France (N=288), Germany (N=618), and Britain (N=302). Participants were interviewed at 6-monthly intervals for a total of 2 years. This initial paper describes the methods used and presents clinical and social baseline data.

Results

The clinical and socio-demographic differences between patients from the different countries were small. However, patients from Britain were considerably more likely than their continental counterparts to have a history of homelessness, rooflessness or imprisonment, even when social and clinical differences between the samples were controlled.

Conclusions

The samples were largely similar in clinical terms. Thus, the social differences between the samples seem likely to be due more to the societal context and may reflect relatively benign situations in the continental locations of our study.

References

  1. 1.
    Addington D, Addington J, Schissel B (1990) A depression rating scale for schizophrenics. Schizophr Res 3:247–251CrossRefPubMedGoogle Scholar
  2. 2.
    Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992) Reliability and validity of a depression rating scale for schizophrenia. Schizophr Res 6:201–208CrossRefPubMedGoogle Scholar
  3. 3.
    American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn, revised. American Psychiatric Association, Washington, DCGoogle Scholar
  4. 4.
    Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:276–672Google Scholar
  5. 5.
    Bauer M, Kunze H, von Cranach M, Fritze J, Becker T (2001) Psychiatric reform in Germany. Acta Psychiatr Scand 104(Suppl 401):27–39CrossRefGoogle Scholar
  6. 6.
    Bebbington PE, Marsden L, Brewin CR (1997) The need for psychiatric treatment in the general population: the Camberwell Needs for Care Survey. Psychol Med 27:821–834CrossRefPubMedGoogle Scholar
  7. 7.
    Bebbington PE, Brugha TS, Hill T, Marsden L, Window S (1999) A validation of the Health of the Nation Outcome Scales (HoNOS). Br J Psychiatry 174:389–394PubMedGoogle Scholar
  8. 8.
    Bebbington P, Brugha T, Jenkins R, Lewis G, Farrell M, Meltzer H (2000) Neurotic disorders and the use of services: a report from the National Survey of Psychiatric Morbidity. Psychol Med 30:1369–1376CrossRefPubMedGoogle Scholar
  9. 9.
    Bebbington PE, Kuipers L (2003) Schizophrenia and psychosocial stresses. In: Hirsch SR, Weinberger D (eds) Schizophrenia. Blackwell, Oxford, pp 611–634Google Scholar
  10. 10.
    Beecham J, Knapp M (1992) Costing psychiatric interventions. In: Thornicroft G, Brewin CR, Wing JK (eds) Measuring mental health needs. Gaskell, LondonGoogle Scholar
  11. 11.
    Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D (1992) The posItive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. J Nerv Mental Disord 180:723–728Google Scholar
  12. 12.
    Brazier J, Jones N, Kind P (1993) Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Q Life Res 2:169–180CrossRefGoogle Scholar
  13. 13.
    Burns T, Fiander M, Kent A, Ukoumunne OC, Byford S, Fahy T, Kumar KR (2000) Effects of case-load size on the process of care of patients with severe psychotic illness. Report from the UK700 trial. Br J Psychiatry 177:427–433PubMedGoogle Scholar
  14. 14.
    Chisholm D, Knapp M (2002) The economics of schizophrenia care in Europe: the EPSILON study. Epidemiol Psychiatr Soc 11:12–17Google Scholar
  15. 15.
    Cooper JE, Kendell RE, Gurland BJ, Sharpe L, Copeland JRM, Simon R (1972) Psychiatric diagnosis in New York and London. Maudsley Monograph No. 20. Oxford University Press, LondonGoogle Scholar
  16. 16.
    Dausch BM, Miklowitz DJ, Richards JA (1996) Global Assessment of Relational Functioning Scale (GARF): II. Reliability and validity in a sample of families of bipolar patients. Fam Proc 35:175–189CrossRefGoogle Scholar
  17. 17.
    Draine J, Salzer MS, Culhane DP, Hadley TR (2002) Role of social disadvantage in crime, joblessness, and homelessness among persons with serious mental illness. Psychiatr Serv 53:565–573CrossRefPubMedGoogle Scholar
  18. 18.
    Gaite L, Vazquez-Barquero JL, Borra C, Ballesteros J, Schene A, Welcher B, Thornicroft G, Becker T, Ruggeri M, Herran A, Koeter M, Meijer K, Monden M, Sijsenaar M, Van-Wijngaarden B, Knudsen HC, Larsen A, Martiny K, Schou C, Beecham J, Brooks L, Chisholm D, Griffiths G, Grove J, Knapp M, Leese M, McCrone P, Padfield S, White IR, Arrizabalaga AA, Castanedo SH, Retuerto MP, Bourgon EV, Amaddeo F, Bisoffi G, Cristofalo D, Dall'Agnola R, Lasalvia A, Tansella M (2002) Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand 105:283–292CrossRefPubMedGoogle Scholar
  19. 19.
    Garratt AM, Ruta DA, Abdalla ME, Buckingham JK, Russell IT (1993) The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? Br Med J 306:1440–1444Google Scholar
  20. 20.
    Goldman HH, Skodol AE, Lave TR (1992) Revising AXIS V for DSM-IV: a review of measures of social functioning. Am J Psychiatr 149:1148–1156PubMedGoogle Scholar
  21. 21.
    Group for the Advancement of Psychiatry Committee on the Family (1996) Global Assessment of Relational Functioning Scale (GARF): I. Background and rationale. Group for the Advancement of Psychiatry Committee on the Family. Fam Proc 35:155–172Google Scholar
  22. 22.
    Guy W (1976) ECDEV Assessment manual for psychopharmacology. Revised DHEW Pub (AOM). National Institute for Mental Health, Rockville MDGoogle Scholar
  23. 23.
    Harding CM, Hall GM (1997) Long-term outcome studies of schizophrenia: do females continue to display better outcome as expected. Int Rev Psychiatry 9:409–418CrossRefGoogle Scholar
  24. 24.
    Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H (1994) Validity of EuroQol—a generic health status instrument—in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol 33:655–662PubMedGoogle Scholar
  25. 25.
    Jenkinson C, Coulter A, Wright L (1993) Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. Br Med J 306:1437–1440Google Scholar
  26. 26.
    Johnson S, Kuhlmann R, EPCAT Group (2000) The European Service Mapping Schedule (ESMS): development of an instrument for the description and classification of mental health services. Acta Psychiatr Scand 102(Suppl 405):14–23CrossRefGoogle Scholar
  27. 27.
    Johnson S, Zinkler M, Priebe S (2001) Mental health service provision in England. Acta Psychiatr Scand 104(Suppl 410):47–55CrossRefGoogle Scholar
  28. 28.
    Kay SR, Opler LA, Lindenmayer JP (1987) The Positive and Negative Syndromes Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276PubMedGoogle Scholar
  29. 29.
    Kay SR, Opler LA, Lindenmayer JP (1989) The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 155:59–65Google Scholar
  30. 30.
    Kay SR (1991) Positive and negative syndromes in schizophrenia. Brunner/Mazel, New YorkGoogle Scholar
  31. 31.
    Knapp M (1997) Costs of schizophrenia (review). Br J Psychiatry 171:509–518PubMedGoogle Scholar
  32. 32.
    Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A, Thornicroft G, Vazquez-Barquero JL, Knudsen HC, Becker T (2002) EPSILON. European psychiatric services: inputs linked to outcome domains and needs: comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European psychiatric services: inputs linked to outcome domains and needs. Acta Psychiatr Scand 105:42–54CrossRefPubMedGoogle Scholar
  33. 33.
    Kovess V, Boisguerin B, Antoine D, Reynauld M (1995) Has the sectorization of psychiatric services in France really been effective? Soc Psychiatry Psychiatr Epidemiol 30:132–138CrossRefPubMedGoogle Scholar
  34. 34.
    Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI (1985) Assessment of tardive dyskinesia using the abnormal involuntary movement scale. J Nerv Ment Dis 173:353–357PubMedGoogle Scholar
  35. 35.
    Lang FH, Forbes JF, Murray GD, Johnstone EC (1997) Service provision for people with schizophrenia. I. Clinical and economic perspective. Br J Psychiatry 171:159–164PubMedGoogle Scholar
  36. 36.
    Lehman AF (1983) The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Eval Program Plann 6:143–151CrossRefPubMedGoogle Scholar
  37. 37.
    Marwaha S, Johnson S (2004) Schizophrenia and employment. A review. Soc Psychiatry Psychiatr Epidemiol 39:337–349CrossRefPubMedGoogle Scholar
  38. 38.
    Marwaha S, Johnson S, Bebbington P, Angermeyer M, Brugha T, Azorin J-M, Killian R, Hansen K, Toumi M (2005) Characteristics and correlates of employment in people with schizophrenia. Findings from the international EuroSC study. Br J Psychiatry (in press)Google Scholar
  39. 39.
    Mason P, Harrison G, Glazebrook C, Medley I, Croudace T (1996) The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISoS) coordinated by the World Health Organization. Br J Psychiatry 169:580–586PubMedGoogle Scholar
  40. 40.
    McCrone P, Leese M, Thornicroft G, Schene A, Knudsen HC, Vazquez-Barquero JL, Tansella M, Becker T, Chisholm D (2001) A comparison of needs of patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand 103:370–379CrossRefPubMedGoogle Scholar
  41. 41.
    Norman RMG, Malla AK, Cortese L, Diaz F (1996) A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophr Res 19:73–85CrossRefPubMedGoogle Scholar
  42. 42.
    Overall JE, Gorham DR (1962) Brief Psychiatric Rating Scale. Psychol Rep 10:799–812Google Scholar
  43. 43.
    Phelan M, Slade M, Thornicroft G, Dunn G, Holloway F, Wykes T, Strathdee G, Loftus L, McCrone P, Hayward P (1995) The Camberwell Assessment of Need (CAN). The validity and reliability of an instrument to assess the needs of people with severe mental illness. Br J Psychiatry 167:589–595PubMedGoogle Scholar
  44. 44.
    Psychopharmacology Research Branch NIMH (1976) Abnormal Involuntary Movement Scale (AIMS). In: Guy W (ed) Assessment manual for psychopharmacology (revised). NIMH, Rockville, MD, pp 534–537Google Scholar
  45. 45.
    Ruggeri M, Lasalvia A, Bisoffi G, Thornicroft G, Gazquez-Barquero JL, Becker T, Knapp M, Knudsen HC, Schene A, Tansella M (2003) Satisfaction with mental health services among people with schizophrenia in five European sites: results from the EPSILON study. Schizophr Bull 29:229–245PubMedGoogle Scholar
  46. 46.
    Salvador-Carulla L, Haro JM, Cabases J, Madoz V, Sacristan JA, Vazquez-Barquero JL (1999) Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in North-East Spain. PSICOST Group. Acta Psychiatr Scand 100:335–343PubMedGoogle Scholar
  47. 47.
    Sartorius N, Kuyken W (1994) Translation of health status instruments. In: Orley J, Kuyken W (eds) Quality of life assessment: international perspectives. Springer, Berlin Heidelberg New York, pp 2–18Google Scholar
  48. 48.
    Schene AH (1990) Objective and subjective dimensions of family burden. Towards an integrative framework for research. Soc Psychiatry Psychiatr Epidemiol 25:289–297CrossRefPubMedGoogle Scholar
  49. 49.
    Schene AH, Wijngaarden B (1992) The involvement evaluation questionnaire. Department of Psychiatry, University of Amsterdam, AmsterdamGoogle Scholar
  50. 50.
    Schwarz D, Lellouch J (1967) Explanatory and prognostic attitudes in therapeutic trials. J Chronic Dis 20:637–648CrossRefPubMedGoogle Scholar
  51. 51.
    Simpson S, Angus R (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:11–19PubMedGoogle Scholar
  52. 52.
    Slade M, Phelan M, Thornicroft G (1998) A comparison of needs assessed by staff and an epidemiologically representative sample of patients with psychosis. Psychol Med 28:543–550CrossRefPubMedGoogle Scholar
  53. 53.
    Slade M, Loftus L, Phelan M, Thornicroft G, Wykes T (1999) The Camberwell assessment of need. Gaskell, LondonGoogle Scholar
  54. 54.
    Spitzer RL, Williams JB, Gibbon M, First MB (1992) The Structured Clinical Interview for DSM-III-R (SCID). I: rationale, and description. Arch Gen Psychiatry 49:624–629PubMedGoogle Scholar
  55. 55.
    Thornicroft G, Tansella M, Becker T, Knapp M, Leese M, Schene A, Vazquez-Barquero JL (2004) The personal impact of schizophrenia in Europe. Schizophr Res 69:125–132CrossRefPubMedGoogle Scholar
  56. 56.
    Tracy K, Adler LA, Rotrosen J, Edson R, Lavori P (1997). Interrater reliability issues in multicentre trials. Part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol Bull 33:53–57PubMedGoogle Scholar
  57. 57.
    van Agt HM, Essink-Bot ML, Krabbe PF, Bonsel GJ (1994) Test–retest reliability of health state valuations collected with the EuroQol questionnaire. Soc Sci Med 39:1437–1444Google Scholar
  58. 58.
    Van-Wijngaarden B, Schene A, Koeter M, Becker T, Knapp M, Knudsen HC, Tansella M, Thornicroft G, Vazquez-Barquero JL, Lasalvia A, Leese M (2003) People with schizophrenia in five countries: conceptual similarities and intercultural differences in family caregiving. Schizophr Bull 39:573–586Google Scholar
  59. 59.
    Walsh E, Buchanan A (2003) Criminal and violent behaviour in schizophrenia. In: Murray R, Jones P, Susser E, van Os J, Cannon M (eds) The epidemiology of schizophrenia. CUP, CambridgeGoogle Scholar
  60. 60.
    Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, Frances A (1994) Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull 20:297–310PubMedGoogle Scholar
  61. 61.
    Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablensky A, Regier R, Sartorius N (1990) SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 47:589–593PubMedGoogle Scholar
  62. 62.
    World Health Organization (1973) The international pilot study of schizophrenia. WHO, GenevaGoogle Scholar
  63. 63.
    World Health Organization (1992). SCAN: Schedules for Clinical Assessment in Neuropsychiatry. WHO, GenevaGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Paul E. Bebbington
    • 1
  • Matthias Angermeyer
    • 2
  • Jean-Michel Azorin
    • 3
  • Traolach Brugha
    • 4
  • Reinhold Kilian
    • 5
  • Sonia Johnson
    • 1
  • Mondher Toumi
    • 6
  • Åsa Kornfeld
    • 6
  • EuroSC Research Group
  1. 1.Dept. Mental Health Sciences (Bloomsbury Campus)Royal Free and University College Medical School, UCLLondonUK
  2. 2.Dept. of PsychiatryUniversity of LeipzigLeipzigGermany
  3. 3.SHU Psychiatrie AdultesHôpital Sainte MargueriteMarseilleFrance
  4. 4.Brandon Mental Health Unit, Leicester General Hospital, Section of Social and Epidemiological PsychiatryUniversity of LeicesterLeicesterUK
  5. 5.Klinik und Poliklinik für PsychiatrieUniversität LeipzigLeipzigGermany
  6. 6.Health Economics Dept.ParisFrance

Personalised recommendations